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Abstract
Sticker's sarcoma (also known as transmissible venereal tumor) is a horizontally transmitted
neoplasm of the dog, that is passed with coitus. It is a locally aggressive tumor with a low tendency
to metastatic spread. The most common locations are the genitals, the nose, the perianal area.
Standard treatment consists with chemotherapy with vincristine, however other therapies such as,
cryotherapy, immunotherapy or, in selected cases, radiation therapy, have been reported. In this
article we describe the outcome of a small cohort of canine patients, with chemotherapy resistant
transmissible venereal tumor (TVT), treated with bleomycin selectively driven by trains of biphasic
pulses (electrochemotherapy). Three canine patients, with refractory TVT, entered the study and
received two sessions of ECT under sedation. The pets had local injection of bleomycin at the
concentration of 1.5 mg/ml and five minutes after the chemotherapy, trains of 8 biphasic electric
pulses lasting 50 + 50 μs each, with 1 ms interpulse intervals, were delivered by means of modified
caliper or, for difficult districts, through paired needle electrode. All the patients responded to the
treatment and are still in remission at different times. Electrochemotherapy appears as a safe and
efficacious modality for the treatment of TVT and warrants further investigations.
Introduction
Canine Sticker's tumor is a coitus transmissible disease
that is directly transferred from dog to dog through major
histocompatibility complex barriers and by means of
direct transfer of viable tumor cells from individual to
individual [1]. The transfer is facilitated by the presence of
mucosal lesions (like those occurring during mating), and
can be transmitted by behaviors such as licking or sniffing
[1]. Interestingly, the transmissible agent causing trans-
missible venereal tumor (TVT) is thought to be the tumor
cell itself. Recent articles analyzed several genetic markers
including major histocompatibility (MHC) genes, in
Sticker's sarcomas and matched blood samples [2,3]. In
each case, the tumor resulted genetically distinct from its
host [2,3]. During progressive growth, TVT downmodu-
lates MHC antigen expression and release inhibiting
cytokines that impair the NK function, frequently result-
ing in host's inability to reject the tumor [4-6]. The treat-
ment of election for these neoplasms is chemotherapy
with vincristine however, cryotherapy, immunotherapy
and, in selected cases, radiation therapy have been
reported as well [1,7-10]. A recently published paper
Published: 3 November 2008
Journal of Experimental & Clinical Cancer Research 2008, 27:58 doi:10.1186/1756-9966-27-58
Received: 23 September 2008
Accepted: 3 November 2008
This article is available from: http://www.jeccr.com/content/27/1/58
© 2008 Spugnini et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Experimental & Clinical Cancer Research 2008, 27:58 http://www.jeccr.com/content/27/1/58
Page 2 of 5
(page number not for citation purposes)
reports a response rate to vincristine of 31 out of 38 dogs,
the non responders were treated with doxorubicin; at the
completion of the chemotherapy cycles two dogs still had
viable tumor cells [7].
Biphasic pulses electrochemotherapy (ECT) is a novel
anticancer technique that has been recently investigated
in oncology [11,12]. More recently, our group has investi-
gated the feasibility and efficacy of ECT in companion ani-
mals carrying spontaneously occurring neoplasms,
obtaining an high percentage of responses, many of which
long lasting, even in neoplasms, such as lymphoma and
soft tissue sarcomas, known to be non-responsive to bleo-
mycin, the drug of election [13-29].
On the basis of such results, a study was performed to
assess the potentials of this technique for the treatment or
palliation of canine TVTs that were resistant to systemic
chemotherapy due to the difficulties posed by treating
tumors in the genital district.
Materials and methods
Patient selection
Privately owned veterinary patients with histopathologi-
cally confirmed localized TVT were selected for the study.
Previous informed consent was obtained from the own-
ers, according to the Italian law (116/92). In order to be
enrolled, the patients had to have normal renal and
hepatic function (normal serum blood urea nitrogen
[BUN], creatinine and urine specific gravity as well as nor-
mal liver enzymes and bile acids). Moreover, patients had
to be free of underlying life threatening diseases or other
medical complications (i.e. diabetes mellitus).
Staging process included a thorough anamnesis, physical
examination, complete blood cell count (CBC), serum
biochemistry profile, iliac lymph node aspiration and
cytological examination (if enlarged at ultrasonographic
exam), thoracic radiographs (three projections), and
tumor biopsy. In order to confirm the diagnoses, cytolog-
ical examination of a biopsy (Figure 1), was performed by
one of the authors, subsequently histological examination
of the biopsies was performed following standard proto-
cols, using Hematoxylin/Eosin and Hematoxylin/Van
Gieson stainings by two of the authors.
All the patients had an ultrasonographic evaluation of the
abdomen as well at the time of the enrollment in the
study to rule out underlying disease. The characteristics of
the enrolled patients are summarized in table 1.
Treatment
Patients that entered in the study received two sessions of
ECT one week apart under sedation with medetodimine
and ketamine as per manufacturer's instruction. Briefly
the tumor's bed and the margins for 0.5 cm in all direc-
tions were infiltrated with bleomycin at the concentration
of 1.5 mg/ml. Five minutes after the infiltration, trains of
8 biphasic electric pulses lasting 50 + 50 μs each, with 1
ms interpulse intervals, were delivered by means of mod-
ified caliper electrodes. For particularly difficult districts,
paired needle array electrodes were adopted.
Response to treatment and local toxicity were assessed
prior to each therapy and two weeks after the second ECT.
Criteria for tumor response to therapy are summarized in
Table 2. Patients had monthly rechecks for the first six
months and every third month thereafter. At that time,
abdominal ultrasonographic exam was made to check for
systemic spread. Toxicity was defined as disease processes
that occurred secondary to changes of the tissues within
the treatment field.
A cytology slide of the neoplasm of one of the patients Figure 1
A cytology slide of the neoplasm of one of the 
patients. Note the numerous population of discrete round 
cells. (Diff Quick staining; magnification 100 ×).
Table 1: Individual data and response to electrochemotherapy (ECT) in three dogs with TVT
Signalment (age, sex,) Tumor type and stage Response (Months) Outcome
4 yo, M, Hunting dog T2N0M0 CR 48 Alive, CR
5 yo, M, Mixed Breed T3N0M0 CR 34 Alive, CR
7 yo, M, German Shephard T1N0M0 CR 28 Alive, CR
yo = years old; M = male CR = complete remission;
NB = age is given at the time of presentation;Journal of Experimental & Clinical Cancer Research 2008, 27:58 http://www.jeccr.com/content/27/1/58
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Pulse generator
The "Chemopulse" is built up by a toroidal core trans-
former generating a roughly rectangular pulse which is
split in two halves that are sequentially driven to obtain a
biphasic pulse. The pulses are not singularly produced but
are created in bursts of eight, thus reducing the treatment
time and the overall patient morbidity. The equipment
allows to choose among a broad range of voltages (from
450 to 2450 V) with sequential increases of 200 V and per-
mits to regulate the number of pulses (from 1 to 16) and
the duration of the pulses (50 to 100 μs). The standard
setting is 8 pulses of 50+50 μs at 1300 V/cm. The pulse
repetition frequency is 1 Hz while the frequency of burst
repetition is 1 kHz, resulting in a total burst duration of
7.1 ms [11,13-29].
Electrodes(14)
1) Modified monolateral compass electrode steel, bache-
lite, plastic with perforated metal plates. Dimensions
(Length × Height × Width): 22 × 10 × 1 mm.
Table 2: Tumor response criteria
Complete Remission (CR) – the disappearance of all evidence of cancer in all sites for a defined period of time.
Partial Remission (PR) – the decrease in size of all tumors by 50% or greater as measured by the sum of the product of two diameters of each 
tumor for a defined period of time.
Stable Disease (SD) – the decrease of < 50% or an increase of < 25% in the sum of the product of two diameters for a defined period of time.
Progressive Disease (PD) – the increase of 25% or more in the sum of the product of two diameters for a defined period of time.
A: Close-up image of a 4 year-old male Hunting dog, affected by a large TVT, at presentation Figure 2
A: Close-up image of a 4 year-old male Hunting dog, affected by a large TVT, at presentation. B: the same patient 
after one session of ECT, note the tumor shrinkage. C: the same patient after the second session of ECT, the tumor has been 
replaced by scar tissue. D: the patient' genitals one month after the completion of the two cycles of electrochemotherapy.Journal of Experimental & Clinical Cancer Research 2008, 27:58 http://www.jeccr.com/content/27/1/58
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Vaccine type twin needle array electrode steel and plastic.
Needle length: 20 mm; array diameter: 20 mm.
Results
Three dogs entered the study over a 6 years period; all the
dogs were intact males, the ages were respectively 4, 5 and
7 years. Patients characteristics are summarized in Table 1.
The fine needle aspiration of the lesions yielded a numer-
ous population of discrete round cells (Figure 1) that had
a round nucleus and a variable amount of cytoplasm.
Anamnestically, the first dog had a partial remission after
6 doses of vincristine and two of doxorubicin, the second
had a progressive disease after 4 doses of vincristine and
one of doxorubicin, and the third was enrolled after fail-
ing after 4 doses of vincristine, due to a bad cardiac frac-
tion shortening that prevented the use of anthracyclines.
All the patients had a response to the first ECT session
resulting in tumor shrinkage and decreased bleeding that
evolved into a complete remission after the second ECT
therapy. The complete responses lasted from 28 months
to 48 months. Throughout the study, pulse-mediated ble-
omycin chemotherapy has been well tolerated by the
enrolled patients, showing remarkable efficacy, while the
only toxicity identified so far, is limited to mild swelling
and erythema that subsided within 3–4 days after ECT in
patient number 1. The therapy allowed the restoration of
continence in two dogs and allowed a physiological uri-
nation in all the patients within 5 days from the first ECT.
Furthermore, in all the patients, ECT has been instrumen-
tal to reduce the penile bleeding (Figure 2) thus, almost
immediately, greatly improving the dogs' quality of life.
Discussion
Electrochemotherapy is a novel technique for cancer treat-
ment or palliation that showed high efficacy and low tox-
icity. Its ease of administration associated with its
affordable cost that enables clinicians to treat again previ-
ously electroporated areas without side effects like
cheloids, profuse bleeding, impaired wound healing like
those observed in case of re-irradiation of tumors both in
pets and humans [16,24,27], make it an appealing alter-
native to standard anticancer options. In the present
study, electrochemotherapy, has proven to be a low toxic-
ity therapy allowing local tumor control without signifi-
cant local or systemic side effects. To the best of the
authors' knowledge this is the first study on the adoption
of ECT for the palliation/treatment of cytologically or his-
tologically confirmed TVTs in a spontaneous canine geni-
tal tumor model. Despite the low number of enrolled
patients, the long term responses obtained in all dogs with
refractory disease are worth of mention. Further studies,
investigating other tumor types involving the genitals, are
needed to improve ECT control by exploring new proto-
cols and drugs also in view of the possible translation of
data to humans [24,27].
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